FDA tentatively approves Perrigo psoriasis treatment
Sales of the ethical version of the treatment, Olux, totaled $78 million in the twelve months ending July.
Eitan Tapiro 3 Sep 06 10:53
Perrigo Co. (Agis Industries) (Nasdaq:PRGO; TASE:PRGO) announced on Friday that it had been granted tentative approval from the US Food and Drug Administration (FDA) on its abbreviated new drug application (ANDA) for Clobetasol Propionate Topical Foam, 0.05%., for the treatment of scalp dermatoses. The ethical version of the drug, Olux is marketed by Connectics Corporation (Nasdaq: CNCT) and had sales totaling $78 million in the twelve months ending July.
If successful in the legal action, and upon final approval, Perrigo expects to be granted 180 days of generic marketing exclusivity. On October 19, 2005, Connetics filed suit in the US District Court of New Jersey to prevent Perrigo from proceeding with the commercialization of its product. Litigation is currently ongoing.
Published by Globes [online], Israel business news - www.globes.co.il - on September 3, 2006
Sunday, September 03, 2006
Subscribe to:
Posts (Atom)
